Updates on the Treatment of Drug-Susceptible and Drug-Resistant Tuberculosis: An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline
<b>Background:</b> On the basis of recent clinical trial data for the treatment of drug-susceptible and drug-resistant tuberculosis (TB), the American Thoracic Society, U.S. Centers for Disease Control and Prevention, European Respiratory Society, and Infectious Diseases Society of America have updated clinical practice guidelines for TB treatment in children and adults in settings in which mycobacterial cultures, molecular and phenotypic drug susceptibility tests, and radiographic studies, among other diagnostic tools, are available on a routine basis. <b>Methods:</b> A Joint Panel representing multiple interdisciplinary perspectives convened with American Thoracic Society methodologists to review evidence and make recommendations using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) and GRADE-ADOLOPMENT (adoption, adaptation, and, as needed, <i>de novo</i> development of recommendations) methodology. <b>Results:</b> New drug-susceptible TB recommendations include the use of a novel 4-month regimen for people with pulmonary TB and a shortened 4-month regimen for children with nonsevere TB. Drug-resistant TB recommendation updates include the use of novel regimens containing bedaquiline, pretomanid, and linezolid with or without moxifloxacin. <b>Conclusions:</b> All-oral, shorter treatment regimens for TB are now recommended for use in eligible individuals.
Authors
- Ibrahim Abubakar (ORCID: https://orcid.org/0000-0002-0370-1430)
- Ioannis Konstantinidis (ORCID: https://orcid.org/0000-0001-6785-1318)
- Raquel Duarte (ORCID: https://orcid.org/0000-0003-2257-3099)
- Payam Nahid (ORCID: https://orcid.org/0000-0003-2811-1311)
- Farah M. Parvez (ORCID: https://orcid.org/0000-0003-1211-5043)
- Terence Chorba (ORCID: https://orcid.org/0000-0001-7722-0958)
- Angela M. Starks (ORCID: https://orcid.org/0000-0001-9606-5623)
- Hassan Chami (ORCID: https://orcid.org/0000-0002-9239-2528)
- Carlos Acuña-Villaorduña
- Anthony J. Garcia‐Prats (ORCID: https://orcid.org/0000-0002-9280-1950)
- Kelly Holland (ORCID: https://orcid.org/0000-0002-9610-1134)
- Charles L. Daley (ORCID: https://orcid.org/0000-0003-3324-926X)
- Jussi Saukkonen (ORCID: https://orcid.org/0009-0001-4200-315X)
- Giovanni Battista Migliori (ORCID: https://orcid.org/0000-0002-2597-574X)
- Sonal S. Munsiff (ORCID: https://orcid.org/0000-0002-7493-9163)
- Jonathan M. Wortham (ORCID: https://orcid.org/0000-0003-0355-5290)
- Manoj J. Mammen (ORCID: https://orcid.org/0000-0003-0343-3234)
- Marc Lipman (ORCID: https://orcid.org/0000-0001-7501-4448)
- Shuhua Wang (ORCID: https://orcid.org/0000-0001-8006-2401)
- Wendy Carr
- Giovanni Sotgiu (ORCID: https://orcid.org/0000-0002-1600-4474)
- Pennan M. Barry
- S. Thakore (ORCID: https://orcid.org/0000-0001-9749-7479)
- Adrienne E. Shapiro (ORCID: https://orcid.org/0000-0002-3106-1258)
- Jeffrey R. Starke (ORCID: https://orcid.org/0000-0001-6218-6697)
- Mayara Lisboa Bastos (ORCID: https://orcid.org/0000-0003-0582-8870)
- Lisa Chen (ORCID: https://orcid.org/0000-0001-6804-0111)
- Carla A. Winston
Publication Details
- Journal
- American Journal of Respiratory and Critical Care Medicine
- Published
- 2024-12-30
- DOI
- https://doi.org/10.1164/rccm.202410-2096st
- Citations
- 84
- Primary Topic
- Tuberculosis Research and Epidemiology
- Type
- article
- Field-Weighted Citation Impact
- 32.68
Funders
- U.S. Department of Health and Human Services
- United States Agency for International Development
- U.S. Department of Veterans Affairs
- Bill and Melinda Gates Foundation
- Cystic Fibrosis Foundation
- American Thoracic Society
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- California Department of Public Health
- Yale University
- Patient-Centered Outcomes Research Institute
- Infectious Diseases Society of America
- Ohio State University
- University of Wisconsin-Madison
- University of Washington
- Johns Hopkins University
- University of Pittsburgh
- University of Rochester
- COPD Foundation
- McGill University
- Faculty of Medicine, McGill University
- National Jewish Health
- Texas Biomedical Research Institute
- MannKind Corporation
- Insmed
- University College London
- Universiteit Stellenbosch
- Università degli Studi di Sassari
- Universidade do Porto
- Administração Regional de Saúde do Norte, Ministério da Saúde
- National Institutes of Health
- Centers for Disease Control and Prevention
- Genentech
- School of Medicine and Public Health, University of Wisconsin-Madison
- University of California, San Francisco
- Max Rady College of Medicine, University of Manitoba
- Faculty of Medicine and Health, University of Sydney
- National Institute of Allergy and Infectious Diseases
- National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
- University of Colorado School of Medicine, Anschutz Medical Campus